Our Board of Directors

Bob Azelby

Non-Executive Director

Bob Azelby joined the Board of Directors in June 2023.

Mr. Azelby is an experienced Chief Executive Officer and veteran board member who has spent over 30 years in the biopharmaceutical industry.

He served as President and Chief Executive Officer of Eliem Therapeutics, Inc., from October 2020 to February 2023. Prior to Eliem, he was the Chief Executive Officer of Alder Biopharmaceuticals, Inc., from June 2018 until it was acquired by H. Lundbeck in 2019. Before joining Alder BioPharmaceuticals, Mr. Azelby was the Chief Commercial Officer of Juno Therapeutics for three years until it was acquired by Celgene Corporation. Prior to Juno, he spent 15 years in commercial roles at Amgen, Inc.

Mr. Azelby serves on the boards of directors of Clovis Oncology, Inc., and Chinook Therapeutics, Inc. Previously, he served on the boards of directors for Eliem Therapeutics, Alder BioPharmaceuticals, Cascadian Therapeutics, Inc., and Immunomedics, Inc. He holds a BA in Economics and Religious Studies from the University of Virginia and an MBA from Harvard Business School.

Back to Our Board of Directors